Skip to main content
SpringerLink
Log in

The 2008 clinical type 2 diabetes guidelines from the Canadian Diabetes Association (CDA) include the new class of DPP-IV* inhibitors.

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Merck Frosst.2008 Canadian Diabetes Association clinical practice guidelines now include new class of DPP-4 inhibitors. Media Release: 19 Sep 2008. Available from: URL: http://www.merckfrosst.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The 2008 clinical type 2 diabetes guidelines from the Canadian Diabetes Association (CDA) include the new class of DPP-IV* inhibitors.. Pharmacoecon. Outcomes News 563, 2 (2008). https://doi.org/10.2165/00151234-200805630-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200805630-00003

Keywords

Search

Navigation